Axsome Therapeutics (AXSM) EBT (2015 - 2026)

Axsome Therapeutics has reported EBT for 12 years, with the latest figure at -$64.5 million in Q1 2026.

• Quarterly EBT fell 8.63% year-over-year to -$64.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$188.8 million (up 32.12% YoY) and the FY2025 annual result came in at -$183.7 million, up 36.02% from the prior year.
• EBT declined to -$64.5 million in Q1 2026 per AXSM's latest filing, from -$28.1 million in the prior quarter.
• Over five years, EBT peaked at -$8.6 million in Q1 2023 and troughed at -$99.0 million in Q4 2023.
• A 5-year average of -$56.5 million and a median of -$61.2 million in 2022 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2024: EBT jumped 81.04% in 2022, then plunged 691.35% in 2024.
• Over 5 years, EBT stood at -$61.2 million in 2022, then slumped by 61.62% to -$99.0 million in 2023, then increased by 24.4% to -$74.8 million in 2024, then jumped by 62.41% to -$28.1 million in 2025, then plunged by 129.45% to -$64.5 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$64.5 million, -$28.1 million, and -$47.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.